- Home
- Publications
- Publication Search
- Publication Details
Title
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 15, Issue 11, Pages 1365
Publisher
MDPI AG
Online
2022-11-08
DOI
10.3390/ph15111365
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
- (2022) Alice B. Gottlieb et al. ACTA DERMATO-VENEREOLOGICA
- Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study
- (2022) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?
- (2022) Zeev Elkoshi Frontiers in Immunology
- Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis
- (2022) Hossein Azadeh et al. INFLAMMOPHARMACOLOGY
- Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study
- (2022) Peter Foley et al. Dermatology and Therapy
- IL‐17 inhibitors and inflammatory bowel diseases: a post‐marketing study in Vigibase®
- (2021) Nadine Petitpain et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Aphthous stomatitis in a man with psoriatic arthritis
- (2021) Cécile Fermon et al. AMERICAN JOURNAL OF MEDICINE
- Concurrent chronic hyperplastic candidosis and oral lichenoid lesion as adverse events of secukinumab therapy
- (2021) CS Farah AUSTRALIAN DENTAL JOURNAL
- Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients
- (2021) Ioana A Onac et al. RHEUMATOLOGY
- Secukinumab and infectious adverse effects: A real‐life experience of 63 psoriasis patients
- (2021) Tulin Ergun et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- The risk of malignancy in secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five‐year clinical trial and post‐marketing surveillance data
- (2021) M. Lebwohl et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis
- (2021) Christopher E M Griffiths et al. LANCET
- Bimekizumab versus Secukinumab in Plaque Psoriasis
- (2021) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infective dermatitis after treatment with secukinumab
- (2021) T. O. Utiyama et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Secukinumab‐induced multiple lentigines in areas of resolved psoriatic plaques: a case report and literature review
- (2021) Sanquan Zhang et al. Dermatologic Therapy
- Skin and soft tissue infections in biological therapy for psoriasis—A case report and systematic review of the literature
- (2021) Shani Fisher et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Cutaneous sarcoidosis after application of secukinumab in a patient with plaque psoriasis
- (2021) Jia‐Wei Lu et al. JOURNAL OF DERMATOLOGY
- Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis
- (2021) Francesco Bellinato et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
- (2021) Bruna Lavinas Sayed Picciani et al. BMC Oral Health
- Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis
- (2021) Eduardo V. Mendes Roncada et al. Case Reports in Dermatology
- Bilateral infectious scleritis from Histoplasma capsulatum in an immunosuppressed uveitis patient
- (2021) Kevin Wang et al. American Journal of Ophthalmology Case Reports
- Epithelial herpes simplex keratitis in a patient on treatment with secukinumab for psoriasis: An effect of interleukin-17 blockade?
- (2021) Preema Sinha et al. Indian Journal of Dermatology Venereology & Leprology
- Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
- (2021) Hannah A. Blair PEDIATRIC DRUGS
- Interleukin-17A and Keratinocytes in Psoriasis
- (2020) Masutaka Furue et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Off-Label Dermatologic Uses of IL-17 Inhibitors
- (2020) Kevin K. Wu et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S)
- (2020) Joel M. Gelfand et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis
- (2020) Sofie Vaengebjerg et al. JAMA Dermatology
- Interleukin‐17 is a potential player and treatment target in severe chronic spontaneous urticaria
- (2020) DA Sabag et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2‐year period
- (2020) M. Megna et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study
- (2020) Maria Antonietta Barbieri et al. Journal of Clinical Medicine
- Staphylococcal toxic shock syndrome in a child with interleukin‐17 inhibitor treatment for psoriasis
- (2020) María Sánchez Martín et al. PEDIATRIC DERMATOLOGY
- Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
- (2020) Hideki Fujita et al. JOURNAL OF DERMATOLOGY
- Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab
- (2020) Chaitra Srinivas et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Secukinumab-induced scleroderma: a case report
- (2020) Nadia Elias et al. RHEUMATOLOGY
- Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
- (2020) Boni E. Elewski et al. JAMA Dermatology
- Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
- (2020) Ralph Adams et al. Frontiers in Immunology
- 17965 An exploratory, open-label study of secukinumab in patients with moderate to severe papulopustular rosacea
- (2020) Anusha M. Kumar et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
- (2020) Taoming Liu et al. Frontiers in Immunology
- Two-Year US Pharmacovigilance Report on Brodalumab
- (2020) Mark Lebwohl et al. Dermatology and Therapy
- Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
- (2020) Anja St Clair-Jones et al. Rheumatology and Therapy
- Injection site reactions with the use of biological agents
- (2019) Elena Thomaidou et al. Dermatologic Therapy
- Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions
- (2019) Kevin K. Wu et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Pseudolymphoma induced by secukinumab for treatment of chronic plaque psoriasis
- (2019) William C Cranwell et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- The IL-17 Family of Cytokines in Health and Disease
- (2019) Mandy J. McGeachy et al. IMMUNITY
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
- (2019) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report
- (2019) D Currado et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- The Role of Inflammation in Depression and Fatigue
- (2019) Chieh-Hsin Lee et al. Frontiers in Immunology
- A case of new onset ulcerative colitis following secukinumab treatment
- (2019) David N Johnston et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- (2019) Michael M. Ward et al. Arthritis & Rheumatology
- Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
- (2019) Fan Bai et al. Journal of Immunology Research
- Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients
- (2019) Gerard Bruin et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Secukinumab‐induced paradoxical hidradenitis suppurativa
- (2019) Francisco J. Navarro‐Triviño et al. Dermatologic Therapy
- Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis
- (2019) Shusuke Uchida et al. EUROPEAN JOURNAL OF DERMATOLOGY
- The role of interleukin-17 in tumor development and progression
- (2019) Junjie Zhao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Association of Psoriasis With the Risk of Developing or Dying of Cancer
- (2019) Alex M. Trafford et al. JAMA Dermatology
- Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis
- (2019) Elsie Grace et al. Dermatology and Therapy
- Severe colitis complicating secukinumab (Cosentyx ® ) therapy
- (2019) A. S. W. Lee et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
- (2018) R. B. Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab
- (2018) D. Hoshina et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
- (2018) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease events after exposure to the IL-17 inhibitors, secukinumab and ixekizumab: A post-marketing analysis from the RADAR (Research on Adverse Drug events And Reports) Program
- (2018) Kelsey A. Orrell et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Breech at the Border: An atypical case of invasive Haemophilus influenzae in a patient on a novel immunotherapeutic
- (2018) Jessica Howard-Anderson et al. Open Forum Infectious Diseases
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
- (2018) Andrew Blauvelt et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Atopic-like dermatitis after Secukinumab injection: a case report
- (2018) Martina Burlando et al. Dermatologic Therapy
- Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab
- (2018) Kayo Jin et al. JOURNAL OF DERMATOLOGY
- Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris
- (2018) M. Hayashi et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab-Associated Crystalline Corneal Deposition
- (2018) Barry Power et al. CORNEA
- Association of Psoriasis With Inflammatory Bowel Disease
- (2018) Yun Fu et al. JAMA Dermatology
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
- (2018) Jasvinder A. Singh et al. Arthritis & Rheumatology
- Secukinumab-induzierter subakut-kutaner Lupus erythematodes
- (2017) C. Wehrmann et al. HAUTARZT
- Interleukin-17A Inhibitor–induced Crohnʼs Disease/Behçetʼs Disease–like Lesions
- (2017) Hisashi Shiga et al. INFLAMMATORY BOWEL DISEASES
- Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris
- (2017) Ikko Kajihara et al. JOURNAL OF DERMATOLOGY
- Development of bullous pemphigoid during secukinumab treatment for psoriasis
- (2017) Po-Han Ho et al. JOURNAL OF DERMATOLOGY
- Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors
- (2017) T. Oiwa et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Adverse skin reaction to Secukinumab
- (2017) M.F. Peigottu et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- Opportunistic Infections in Biological Therapy, Risk and Prevention
- (2017) Paul A. Bryant et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Ankylosing spondylitis and the risk of cancer
- (2017) Chih-Cheng Chang et al. Oncology Letters
- Secukinumab-Induced Psoriasiform Eruption
- (2017) Michael J. Sladden et al. JAMA Dermatology
- Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
- (2017) Jillian Frieder et al. Therapeutic Advances in Chronic Disease
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Oral lichen planus associated with candidiasis during secukinumab treatment
- (2016) Takaya Komori et al. JOURNAL OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Evaluating imbalances of adverse events during biosimilar development
- (2016) Alicia M. Vana et al. mAbs
- IL-17-producing γδ T cells enhance bone regeneration
- (2016) Takehito Ono et al. Nature Communications
- Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis
- (2016) Olivia Leigh Quach et al. JAMA Dermatology
- Secukinumab for ankylosing spondylitis and psoriatic arthritis
- (2016) Ennio Lubrano et al. Therapeutics and Clinical Risk Management
- Psoriasis: classical and emerging comorbidities
- (2015) Maria de Fátima Santos Paim de Oliveira et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
- (2015) Peter G. Pappas et al. CLINICAL INFECTIOUS DISEASES
- Biologics and biosimilars
- (2015) Palak K. Patel et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study
- (2014) Seoyoung C Kim et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunology of Psoriasis
- (2014) Michelle A. Lowes et al. Annual Review of Immunology
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
- (2014) J.F. Rahier et al. Journal of Crohns & Colitis
- Adverse reactions to biologic agents and their medical management
- (2014) Onur Boyman et al. Nature Reviews Rheumatology
- IL-17 contributes to neutrophil recruitment but not to control of viral replication during acute mouse adenovirus type 1 respiratory infection
- (2014) Mary K. McCarthy et al. VIROLOGY
- Tumor necrosis factor-α antagonists: Side effects and their management
- (2013) Sunil Dogra et al. Indian Journal of Dermatology Venereology & Leprology
- Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis
- (2013) Eleanor J. Samarasekera et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- The complexity of adverse side-effects to biological agents
- (2012) François Aubin et al. Journal of Crohns & Colitis
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients
- (2012) Talin Barisani-Asenbauer et al. Orphanet Journal of Rare Diseases
- The Th17 Pathway and Inflammatory Diseases of the Intestines, Lungs, and Skin
- (2011) Casey T. Weaver et al. Annual Review of Pathology-Mechanisms of Disease
- Distinct Effects of Anti-Tumor Necrosis Factor Combined Therapy on TH1/TH2 Balance in Rheumatoid Arthritis Patients
- (2011) S. Herman et al. Clinical and Vaccine Immunology
- The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis
- (2011) Yang LIU et al. International Journal of Rheumatic Diseases
- LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study
- (2010) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Cytokine levels in the blood may distinguish suicide attempters from depressed patients
- (2010) Shorena Janelidze et al. BRAIN BEHAVIOR AND IMMUNITY
- Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
- (2010) Reiko M. Onishi et al. IMMUNOLOGY
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- Autoimmunity as a Predisposition for Infectious Diseases
- (2010) Mohan S. Maddur et al. PLoS Pathogens
- Interleukin-17 and Type 17 Helper T Cells
- (2009) Pierre Miossec et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started